BNP Paribas notify of 5.08% shareholding in Galapagos
February 09 2015 - 1:31AM
Mechelen,
Belgium; 9 February 2015 - Galapagos NV (Euronext: GLPG) received a
transparency notification from BNP Paribas.
Pursuant to Belgian transparency
legislation[1], Galapagos
received a transparency notification on 5 February 2015 from BNP
Paribas Investment Partners SA, BNP Paribas Asset Management SAS,
BNP Paribas Investment Partners Belgium SA, BNP Paribas Investment
Partners UK Ltd. and CamGestion SA. BNP Paribas notified that
on 30 January 2015, these entities under their control held
1,538,622 shares, representing 5.08% of the current 30,299,129
outstanding Galapagos shares. This is the first transparency
notice Galapagos received from BNP Paribas.
About
Galapagos
Galapagos (Euronext: GLPG; OTC:
GLPYY) is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action, with a pipeline comprising three Phase 2 programs,
two Phase 1 trials, five pre-clinical studies, and 25 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. In the field of
inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of GLPG0634.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for
the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, currently in Phase 2b studies in RA and in
Phase 2 in Crohn's disease. GLPG1205, a
first-in-class inhibitor of GPR84, is currently being tested in a
Phase 2 proof-of-concept trial in ulcerative colitis
patients. GLPG1690 is a compound that targets pulmonary
diseases and is currently in a Phase 1 trial. AbbVie and
Galapagos also signed a collaboration agreement in cystic fibrosis
to develop and commercialize molecules that address mutations in
the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1
trial, and corrector GLPG2222 is at the pre-clinical candidate
stage. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of
Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
This release may
contain forward-looking statements, including, without limitation,
statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product
candidates, intended product development, clinical activity timing,
and other objectives and explanations, all of which involve certain
risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as
"believes," "anticipates," "expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Among the factors that may result in differences are
the inherent uncertainties associated with competitive
developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
[1]
Belgian Act of 2 May 2007 on the disclosure of major shareholdings
in issuers whose shares are admitted to trading on a regulated
market)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1892604
Galapagos (LSE:GLPG)
Historical Stock Chart
From May 2024 to Jun 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2023 to Jun 2024